A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
Chirality
; 20(6): 762-70, 2008 Jun.
Article
de En
| MEDLINE
| ID: mdl-18200591
ABSTRACT
During the last thirty years, concern over stereoselectivity of drug action has drawn a great deal of interest within the pharmaceutical field due to an improved understanding of the pharmacology and pharmacokinetics of enantiomers. Developing single enantiomers versus racemates or introducing a single enantiomer following the development of the racemic mixture appears to be the new trend. The intellectual property status of single enantiomers from racemates may be unclear. Drug discoverers and patent attorneys must examine the examples of the past to establish an appropriate pathway towards the development and intellectual property protection of chiral drugs. The review will focus on the patenting of an enantiomer in view of the prior art disclosure for the racemic mixture.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Brevets comme sujet
/
Préparations pharmaceutiques
/
Industrie pharmaceutique
Type d'étude:
Prognostic_studies
Pays/Région comme sujet:
America do norte
Langue:
En
Journal:
Chirality
Sujet du journal:
BIOLOGIA MOLECULAR
/
QUIMICA
Année:
2008
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique